A financial advisor glucovance online no prescription Goldman Sachs analysts noted that the potential entrant presents more of a problem for Lantus, which is slated to go off-patent in 2015, than to Levemir. While lack of Interchangeability could limit the biosimilar somewhat, the analysts forecast Lilly's glargine to gain a 6% share of sales in the basal market by 2020 and to be priced at a 15%-20% discount to Lantus. 必須 2000文字以内 [bbs:youtube:(Youtubeの動画ID)]と書くとYoutubeの動画が貼れます。(例:[bbs:youtube:OQThUAQ0UN0])